Corrigendum: Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
Antolín López-Viña
Rocio M. Diaz Campos2* 
Andrea Trisan Alonso
Carlos Melero Moreno- 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
- 2Hospital Universitario 12 de Octubre, Madrid, Spain
- 3Fundación Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
A Corrigendum on
Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
By López-Viña A, Díaz Campos RM, Trisan Alonso A and Melero Moreno C. (2022) Front. Allergy 3:1007593. doi:10.3389/falgy.2022.1007593
Error in Figure/Table
In the published article, there was an error in Figure 1 as published. Many words in Figure 1 appeared underlined. The corrected Figure 1 and its caption appear below.
Figure 1. Algorithm to choose a monoclonal antibody.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: T2 severe asthma, monoclonal antibodies, biomarkers, exacerbations, systemic corticosteroids
Citation: López-Viña A, Diaz Campos RM, Trisan Alonso A and Melero Moreno C (2023) Corrigendum: Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach. Front. Allergy 3:1119941. doi: 10.3389/falgy.2022.1119941
Received: 9 December 2022; Accepted: 15 December 2022;
Published: 10 January 2023.
Approved by: Frontiers in Allergy Editorial Office, Frontiers Media SA, Switzerland
© 2023 López-Viña, Díaz Campos, Trisan Alonso and Melero Moreno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rocio M. Diaz Campos rociomdc80@gmail.com
Specialty Section: This article was submitted to Asthma, a section of the journal Frontiers in Allergy